

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 F26B21/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 F26B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)  
EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GLENN C. EBEY : "A Thermodynamic model for aqueous film-coating" PHARMACEUTICAL TECHNOLOGY, April 1987 (1987-04), page 40,42,43,46,48,50 XP002156193 cited in the application the whole document	1,22,40, 59,62, 64,67,71
A	--- WO 99 18405 A (ASEA BROWN BOVERI ;SIGVANT ROGER (SE); FORSMAN KRISTER (SE)) 15 April 1999 (1999-04-15) the whole document	59,64,71
A	--- EP 0 656 515 A (INNOVATHERM PROF DR LEISENBERG) 7 June 1995 (1995-06-07) the whole document --- -/--	59,64,71

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

21 December 2000

Date of mailing of the international search report

11/01/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Silvis, H

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 651 219 A (BRITISH CERAMIC SERVICE CO) 3 May 1995 (1995-05-03) the whole document ---	59,64,71
A	US 4 704 805 A (KAYA AZMI ET AL) 10 November 1987 (1987-11-10) the whole document ---	59,64,71
A	DE 28 27 843 A (BOLLMANN L KG) 17 January 1980 (1980-01-17) the whole document ---	67
A	EP 0 437 888 A (UNILEVER NV ; UNILEVER PLC (GB)) 24 July 1991 (1991-07-24) ---	
A	GB 2 177 785 A (HALLE ZIEGELWERKE) 28 January 1987 (1987-01-28) ---	
A	US 4 953 298 A (CARTER JOHN L ET AL) 4 September 1990 (1990-09-04) ---	
A	US 4 471 424 A (PERSSON GLEELYN W) 11 September 1984 (1984-09-11) -----	

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9918405	A	15-04-1999	SE 512787 C AU 9468598 A DE 19882708 T SE 9703611 A	15-05-2000 27-04-1999 26-10-2000 04-04-1999
EP 0656515	A	07-06-1995	DE 4340940 A AT 182979 T DE 59408577 D	08-06-1995 15-08-1999 09-09-1999
EP 0651219	A	03-05-1995	NONE	
US 4704805	A	10-11-1987	AU 586125 B AU 7889187 A CA 1275716 A CN 87106973 A EP 0265215 A IN 167694 A JP 63111514 A MX 160711 A	29-06-1989 28-04-1988 30-10-1990 03-08-1988 27-04-1988 08-12-1990 16-05-1988 23-04-1990
DE 2827843	A	17-01-1980	NONE	
EP 0437888	A	24-07-1991	AU 634013 B AU 6931591 A BR 9100149 A CA 2034208 A,C DE 69023629 D DE 69023629 T ES 2080105 T JP 4219101 A JP 7051202 B KR 9506500 B ZA 9100326 A	11-02-1993 18-07-1991 22-10-1991 17-07-1991 21-12-1995 02-05-1996 01-02-1996 10-08-1992 05-06-1995 16-06-1995 30-09-1992
GB 2177785	A	28-01-1987	AT 386405 B AT 103586 A DE 3611563 A FR 2582644 A HU 42039 A,B	25-08-1988 15-01-1988 18-12-1986 05-12-1986 29-06-1987
US 4953298	A	04-09-1990	NONE	
US 4471424	A	11-09-1984	NONE	

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
 US Department of Commerce  
 United States Patent and Trademark  
 Office, PCT  
 2011 South Clark Place Room  
 CP2/5C24  
 Arlington, VA 22202  
 ETATS-UNIS D'AMERIQUE  
 in its capacity as elected Office

Date of mailing (day/month/year) 31 May 2001 (31.05.01)	
International application No. PCT/US00/26933	Applicant's or agent's file reference PU3807WO
International filing date (day/month/year) 29 September 2000 (29.09.00)	Priority date (day/month/year) 29 September 1999 (29.09.99)
Applicant CAMPBELL, Dwayne, A. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
 30 March 2001 (30.03.01)


☐ in a notice effecting later election filed with the International Bureau on:  
 \_\_\_\_\_

2. The election ☒ was  
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No.: (41-22) 740.14.35	Authorized officer Claudio Borton  Telephone No.: (41-22) 338.83.38
---	--

# PATENT COOPERATION TREATY



## PCT

From the INTERNATIONAL SEARCHING AUTHORITY

To:  
GLAXO WELLCOME INC  
Attn. Levy, David J.  
Five Moore Drive, PO Box 13398  
Research Triangle Park  
North Carolina 27709-3398  
UNITED STATES OF AMERICA

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT  
OR THE DECLARATION

(PCT Rule 44.1)

Date of mailing (day/month/year) 11/01/2001	
Applicant's or agent's file reference PU3807W0	<b>FOR FURTHER ACTION</b> See paragraphs 1 and 4 below
International application No. PCT/US 00/26933	International filing date (day/month/year) 29/09/2000
Applicant GLAXO GROUP LIMITED et al.	

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

### Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland  
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.
3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:
- ☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
- ☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority  
European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer  
Pieter Nijhuijs

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

## INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

### When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

### How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

### What documents must/may accompany the amendments?

#### Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.



The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:  
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:  
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:  
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or  
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:  
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

**"Statement under article 19(1)" (Rule 46.4)**

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

**It must be in the language in which the international application is to be published.**

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.


**Consequence if a demand for international preliminary examination has already been filed**

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

**Consequence with regard to translation of the international application for entry into the national phase**

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.



## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>PU3807W0</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 00/ 26933</b>	International filing date (day/month/year) <b>29/09/2000</b>	(Earliest) Priority Date (day/month/year) <b>29/09/1999</b>
Applicant  <b>GLAXO GROUP LIMITED et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. \_\_\_\_\_

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.




From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

IPSS/CPR  
✓poly

PCT

To:

Levy, David J.  
GLAXO WELLCOME INC  
Five Moore Drive, PO Box 13398  
Research Triangle Park  
North Carolina 27709-3398  
ETATS-UNIS D'AMERIQUE



NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 71.1)

PTO/PCT Rec'd 24 MAR 2002

Date of mailing  
(day/month/year) 30.10.2001

Applicant's or agent's file reference  
PU3807WO

IMPORTANT NOTIFICATION

International application No.  
PCT/US00/26933

International filing date (day/month/year)  
29/09/2000

Priority date (day/month/year)  
29/09/1999

Applicant  
GLAXO GROUP LIMITED et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/

European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer

Sääw, S

Tel. +49 89 2399-7297



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)


Applicant's or agent's file reference PU3807WO	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US00/26933	International filing date (day/month/year) 29/09/2000	Priority date (day/month/year) 29/09/1999
International Patent Classification (IPC) or national classification and IPC F26B21/06		
Applicant GLAXO GROUP LIMITED et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 4 sheets, including this cover sheet.  
  
☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☐ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand  30/03/2001	Date of completion of this report  30.10.2001
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Frank, H  Telephone No. +49 89 2399 2695



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US00/26933

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-27 as originally filed

**Claims, No.:**

1-74 as originally filed

**Drawings, sheets:**

1/4-4/4 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

International application No. PCT/US00/26933

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☒ the entire international application.

☐ claims Nos. .

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):  
**see separate sheet**

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

***Ad Item III - Non establishment of opinion with regard to novelty, inventive step and industrial applicability***

1. Although claims 1, 22, 40, 59, 62, 64, 67 and 71 have been drafted as separate independent claims, they appear to relate effectively to the same subject-matter and to differ from each other only with regard to the definition of the subject-matter for which protection is sought. The aforementioned claims therefore lack conciseness. Moreover, lack of clarity of the claims as a whole arises, since the plurality of independent claims makes it impossible to determine the matter for which protection is sought, and places an undue burden on others seeking to establish the extent of the protection.

Hence, claims 1, 22, 40, 59, 62, 64, 67 and 71 do not meet the requirements of Article 6 PCT.

2. Furthermore, the generic term environmental equivalency calculator/controller in claim 1 is unclear. It would appear that this term might mean a standard calculator/controller used for controlling an evaporative drying process. In addition, the term "environmental equivalency" does not appear to be known as being an internationally accepted standard descriptive term but would appear to be vague and unclear leaving the reader in doubt as to the meaning of the technical feature to which it refers, thereby rendering the definition of the subject-matter of said claim unclear (Article 6 PCT).
3. Due to these unclarities it is not possible to perform an examination of the claimed invention as to novelty, inventive step and industrial application.



TO:  
PCT Examination  
International Bureau of WIPO  
34 Chimin des Colombettes  
1211 Geneva 20  
Switzerland

Fax: 011 41 22 740 1435

# Correction to PCT Request before expiration of 30th Month

Applicant's File Reference  
PU3807WO

Applicant  
Glaxo Group Limited

International Application No.  
PCT/US00/26933

International Filing Date:  
29 September 2000

30th Month Deadline:  
29 March 2002

Title: Method and Systems for Controlling  
Evaporative Drying Processes Using  
Environmental Equivalency

## Please correct the following

Box III.1 Please change the address of inventor **Dwayne A. CAMPBELL**

From

Glaxo Wellcome Inc., Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709, US

Change to

GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709, US

Box III.3 Please change the address of inventor **Raymond E. POPE**

From

Glaxo Wellcome Inc., Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709, US

Change to

GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709, US

Box III.4 Please change the address of inventor **Robert Allen STAGNER**

From

Glaxo Wellcome Inc., Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709, US

Change to

GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709, US

Box IV-1 Please change the address of US agents:

From

Glaxo Wellcome Inc., Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709, US

Change to

GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709, US

Please acknowledge receipt of this request by return confirmation to (919) 483-7988 in the United States or mail to the following address:

David J. Levy, VP  
GlaxoSmithKline  
Corporate Intellectual Property Department  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709

If there should be questions, please call (919) 483-2252.

Thank you.  
Sincerely,

  
James P. Riek, Agent for the Applicant

20 Feb 2002  
Date

Express Mail Label No.  
EV022190655US

**FAXED**  
2-20-02

# PCT REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For Receiving Office use only
International Application No.
International Filing Date
Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference  
(if desired) (12 characters maximum) **PU3807WO**

<b>Box No. I TITLE OF INVENTION</b>	
Methods and Systems for Controlling Evaporative Drying Processes Using Environmental Equivalency	
<b>Box No. II APPLICANT</b>	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.) <b>GLAXO GROUP LIMITED</b> Glaxo Wellcome House Berkeley Avenue Greenford, Middlesex UB6 0NN GB	<input type="checkbox"/> This person is also inventor.  Telephone No. 919-483-2370 (US Number)  Facsimile No. 919-483-7988 (US Number)  Teleprinter No.
State (that is, country) of nationality: GB	State (that is, country) of residence: GB
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input checked="" type="checkbox"/> all designated States except the United States of America <input type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
<b>Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)</b>	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.) <b>CAMPBELL, Dwayne A.</b> c/o Glaxo Wellcome Inc. Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709 US	This person is:  <input type="checkbox"/> applicant only <input checked="" type="checkbox"/> applicant and inventor <input type="checkbox"/> inventor only (If this check-box is marked, do not fill in below.)
State (that is, country) of nationality: US	State (that is, country) of residence: US
This person is applicant for the purposes of: <input type="checkbox"/> all designated States <input type="checkbox"/> all designated States except the United States of America <input checked="" type="checkbox"/> the United States of America only <input type="checkbox"/> the States indicated in the Supplemental Box	
<input checked="" type="checkbox"/> Further applicants and/or (further) inventors are indicated on a continuation sheet.	
<b>Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE</b>	
The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as: <input type="checkbox"/> agent <input type="checkbox"/> common representative	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)  <b>LEVY, David J.; DADSWELL, Charles, E.; GRASSLER, Frank P.; BRINK, Robert H.; RIEK, James P.; PRUS, Karen, L; SELBY, Elizabeth; MORGAN, Lorie Ann; BENNETT, Virginia, C.; ROGERS, Christopher R.; DEPPENBROCK, Bonnie L. and LEMANOWICZ, John L. all Glaxo Wellcome Inc., Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709-3398, US</b>	Telephone No. 919-483-2370  Facsimile No. 919-483-7988  Teleprinter No.
<input type="checkbox"/> Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.	

Continuation of Box **II** FURTHER APPLICANTS AND/OR (FURTHER) INVENTOR(S)*If none of the following sub-boxes is used, this sheet is not to be included in the request.*

Name and address: (Familyname followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

MARRANCA, Joseph T.  
3917 Brinkman Drive,  
Wilmington, NC 28405  
US

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:  
US

State (that is, country) of residence:  
US

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Familyname followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

POPE, Raymond E.  
c/o Glaxo Wellcome Inc.  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709  
US

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:  
US

State (that is, country) of residence:  
US

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Familyname followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

STAGNER, Robert Allen  
c/o Glaxo Wellcome Inc.  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709  
US

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:  
US

State (that is, country) of residence:  
US

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Familyname followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of: ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

**Regional Patent**

- ☒ **AP ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, MZ Mozambique, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ **EA Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP European Patent:** AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line) .....

**National Patent (if other kind of protection or treatment desired, specify on dotted line):**

- |  |  |
|--|--|
| <input checked="" type="checkbox"/> AE United Arab Emirates                  | <input checked="" type="checkbox"/> LC Saint Lucia                                     |
| <input checked="" type="checkbox"/> AG Antigua and Barbuda                   | <input checked="" type="checkbox"/> LK Sri Lanka                                       |
| <input checked="" type="checkbox"/> AL Albania .....                         | <input checked="" type="checkbox"/> LR Liberia   |
| <input checked="" type="checkbox"/> AM Armenia .....                         | <input checked="" type="checkbox"/> LS Lesotho .....                                   |
| <input checked="" type="checkbox"/> AT Austria .....                         | <input checked="" type="checkbox"/> LT Lithuania                                       |
| <input checked="" type="checkbox"/> AU Australia .....                       | <input checked="" type="checkbox"/> LU Luxembourg                                      |
| <input checked="" type="checkbox"/> AZ Azerbaijan                            | <input checked="" type="checkbox"/> LV Latvia  |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina .....          | <input checked="" type="checkbox"/> MA Morocco .....                                   |
| <input checked="" type="checkbox"/> BB Barbados                              | <input checked="" type="checkbox"/> MD Republic of Moldova .....                       |
| <input checked="" type="checkbox"/> BG Bulgaria .....                        | <input checked="" type="checkbox"/> MG Madagascar .....                                |
| <input checked="" type="checkbox"/> BR Brazil .....                          | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia ..... |
| <input checked="" type="checkbox"/> BY Belarus .....                         | <input checked="" type="checkbox"/> MN Mongolia  |
| <input checked="" type="checkbox"/> BZ Belize                                | <input checked="" type="checkbox"/> MW Malawi .....                                    |
| <input checked="" type="checkbox"/> CA Canada                                | <input checked="" type="checkbox"/> MX Mexico .....                                    |
| <input checked="" type="checkbox"/> CH and LI Switzerland and Liechtenstein  | <input checked="" type="checkbox"/> MZ Mozambique                                      |
| <input checked="" type="checkbox"/> CN China .....                           | <input checked="" type="checkbox"/> NO Norway  |
| <input checked="" type="checkbox"/> CR Costa Rica .....                      | <input checked="" type="checkbox"/> NZ New Zealand .....                               |
| <input checked="" type="checkbox"/> CU Cuba .....                            | <input checked="" type="checkbox"/> PL Poland .....                                    |
| <input checked="" type="checkbox"/> CZ Czech Republic .....                  | <input checked="" type="checkbox"/> PT Portugal .....                                  |
| <input checked="" type="checkbox"/> DE Germany .....                         | <input checked="" type="checkbox"/> RO Romania   |
| <input checked="" type="checkbox"/> DK Denmark .....                         | <input checked="" type="checkbox"/> RU Russian Federation .....                        |
| <input checked="" type="checkbox"/> DM Dominica                              | <input checked="" type="checkbox"/> SD Sudan   |
| <input checked="" type="checkbox"/> DZ Algeria .....                         | <input checked="" type="checkbox"/> SE Sweden  |
| <input checked="" type="checkbox"/> EE Estonia .....                         | <input checked="" type="checkbox"/> SG Singapore                                       |
| <input checked="" type="checkbox"/> ES Spain .....                           | <input checked="" type="checkbox"/> SI Slovenia .....                                  |
| <input checked="" type="checkbox"/> FI Finland .....                         | <input checked="" type="checkbox"/> SK Slovakia .....                                  |
| <input checked="" type="checkbox"/> GB United Kingdom                        | <input checked="" type="checkbox"/> SL Sierra Leone .....                              |
| <input checked="" type="checkbox"/> GD Grenada                               | <input checked="" type="checkbox"/> TJ Tajikistan .....                                |
| <input checked="" type="checkbox"/> GE Georgia .....                         | <input checked="" type="checkbox"/> TM Turkmenistan .....                              |
| <input checked="" type="checkbox"/> GH Ghana .....                           | <input checked="" type="checkbox"/> TR Turkey .....                                    |
| <input checked="" type="checkbox"/> GM Gambia                                | <input checked="" type="checkbox"/> TT Trinidad and Tobago .....                       |
| <input checked="" type="checkbox"/> HR Croatia .....                         | <input checked="" type="checkbox"/> TZ United Republic of Tanzania                     |
| <input checked="" type="checkbox"/> HU Hungary .....                         | <input checked="" type="checkbox"/> UA Ukraine .....                                   |
| <input checked="" type="checkbox"/> ID Indonesia                             | <input checked="" type="checkbox"/> UG Uganda .....                                    |
| <input checked="" type="checkbox"/> IL Israel .....                          | <input checked="" type="checkbox"/> US United States of America .....                  |
| <input checked="" type="checkbox"/> IN India .....                           | <input checked="" type="checkbox"/> UZ Uzbekistan .....                                |
| <input checked="" type="checkbox"/> IS Iceland                               | <input checked="" type="checkbox"/> VN Viet Nam .....                                  |
| <input checked="" type="checkbox"/> JP Japan .....                           | <input checked="" type="checkbox"/> YU Yugoslavia .....                                |
| <input checked="" type="checkbox"/> KE Kenya .....                           | <input checked="" type="checkbox"/> ZA South Africa .....                              |
| <input checked="" type="checkbox"/> KG Kyrgyzstan                            | <input checked="" type="checkbox"/> ZW Zimbabwe .....                                  |
| <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea |  |
| <input checked="" type="checkbox"/> KR Republic of Korea                     |  |
| <input checked="" type="checkbox"/> KZ Kazakhstan                            |  |

Check-boxes reserved for designating States which have become party to the PCT after issuance of this sheet:



**Precautionary Designation Statement:** In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation(including fees) must reach the receiving Office within the 15-month time



**Supplemental Box**

Supplemental Box is not used, this sheet need not be included in the request.

1. If, in any of the Boxes, the space is insufficient to furnish all the information, in such case, write "Continuation of Box No. ..." [indicate the number of the Box] and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient, in particular:

- (i) if more than two persons are involved as applicants and/or inventors and no "continuation sheet" is available: in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below;
- (ii) if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is applicant;
- (iii) if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is inventor;
- (iv) if, in addition to the agent(s) indicated in Box IV, there are further agents: in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;
- (v) if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," or "certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "continuation" or "continuation-in-part": in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;
- (vi) if, in Box No. VI, there are more than three earlier applications whose priority is claimed: in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI;
- (vii) if, in Box No. VI, the earlier application is an ARIPO application: in such case, write "Continuation of Box No. VI", specify the number of the item corresponding to that earlier application and indicate at least one country party to the Paris Convention for the Protection of Industrial Property or one Member of the World Trade Organization for which that earlier application was filed.

2. If, with regard to the precautionary designation statement contained in Box No. V, the applicant wishes to exclude any State(s) from the scope of that statement: in such case, write "Designation(s) excluded from precautionary designation statement" and indicate the name or two-letter code of each State so excluded.


3. If the applicant claims, in respect of any designated Office, the benefits of provisions of the national law concerning non-prejudicial disclosures or exceptions to lack of novelty: in such case, write "Statement concerning non-prejudicial disclosures or exceptions to lack of novelty" and furnish that statement below.

Continuation of Box IV:

HESKETH, Alan (GB); CRAWLEY, Karen (GB); DOLTON, Peter I. (GB); DAWSON, Hugh B. (GB); FILLER, Wendy Anne (GB); FISHER, Christiane Elizabeth (GB); HACKETT, Ruth Elizabeth (GB); HAMMETT, Audrey G. C. (GB); HOCKLEY, Siân Catherine (GB); LANE, Graham M. H. (GB); LEAROYD, Stephanie Anne (GB); QUILLIN, Helen Kaye (GB); REED, Michael A. (GB); REES, Marion (GB); STOTT, Michael John (GB); STUART, Graham (GB); TEUTEN, Andrew J. (GB); THORNLEY, Rachel M. (GB); and VOLCKMAN, Janis Florence (GB) c/o Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 ONN, Great Britain

Continuation of Box VIII:

Inventor Joseph T. MARRANCA was unavailable for signature of POA at this time. A second transmission to be filed.

  
Christopher P. Rogers  
Agent for Applicant




Box No. VI PRIORITY CLAIM				
Filing date of earlier application (day/month/year)		Number of earlier application	Further priority claims are indicated in the Supplemental Box.	
			Where earlier application is:	
			national application: country	national application: regional Office
			international application: receiving Office	
item (1)	29/09/99 29 September 1999	60/156,673	US	
item (2)				
item (3)				

☒ The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s): (1)

\* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box.

Box No. VII INTERNATIONAL SEARCHING AUTHORITY		
Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):	Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):	
ISA/EP	Date (day/month/year)	Number Country (or regional Office)

Box No. VIII CHECK LIST: LANGUAGE OF FILING	
This international application contains the following number of sheets:	This international application is accompanied by the item(s) marked below:
request : 5	1. <input checked="" type="checkbox"/> fee calculation sheet
description (excluding sequence listing part) : 27	2. <input checked="" type="checkbox"/> separate signed power of attorney <b>Campbell, Pope, Stagner</b>
claims : 11	3. <input type="checkbox"/> copy of general power of attorney; reference number, if any:
abstract : 1	4. <input checked="" type="checkbox"/> statement explaining lack of signature
drawings : 4	5. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s):
sequence listing part of description : 0	6. <input type="checkbox"/> translation of international application into (language):
Total number of sheets : 48	7. <input type="checkbox"/> separate indications concerning deposited microorganism or other biological material
	8. <input type="checkbox"/> nucleotide and/or amino acid sequence listing in computer readable form
	9. <input checked="" type="checkbox"/> other (specify): Copy of GGL Resolution
Figure of the drawings which should accompany the abstract:	Language of filing of the international application: English

Box No. IX SIGNATURE OF APPLICANT OR AGENT	
Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).	
 Christopher P. Rogers, Agent	

For receiving Office use only	
1. Date of actual receipt of the purported international application:	2. Drawings: <input type="checkbox"/> received: <input type="checkbox"/> not received:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	
4. Date of timely receipt of the required corrections under PCT Article 11(2):	
5. International Searching Authority (if two or more are competent): ISA/	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid.

For International Bureau use only	
Date of receipt of the record copy by the International Bureau:	